A Phase 3, Exercise Capacity Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension (PAH)
Phase of Trial: Phase III
Latest Information Update: 06 Aug 2018
At a glance
- Drugs Ralinepag (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Acronyms ADVANCE CAPACITY 302
- Sponsors Arena Pharmaceuticals
- 06 Aug 2018 According to an Arena Pharmaceuticals media release, the company expects to initiate this study in Q4:18.
- 15 May 2018 New trial record
- 09 May 2018 According to an Arena Pharmaceuticals media release, the study is expected to be initiated in H2 2018.